Filing Flows › Akebia Therapeutics (AKBA) › Free cash flow
Akebia Therapeutics (AKBA) free cash flow by quarter
Akebia Therapeutics' free cash flow was $1.6M in Q3 2026 (third quarter 2026), -34% from Q2 2026. Over the last 5 quarters it ranged from $1.6M (Q3 2026) to $31.1M (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.6M | -34% | -94% |
| Q2 2026 | $2.4M | -92% | -89% |
| Q4 2025 | $31.1M | +11% | — |
| Q3 2025 | $28.0M | +26% | — |
| Q2 2025 | $22.2M | — | — |
Q3 2026 at a glance
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Akebia Therapeutics' free cash flow?
Akebia Therapeutics' free cash flow was $1.6M in Q3 2026 (third quarter 2026), -34% from Q2 2026.
How has Akebia Therapeutics' free cash flow changed?
Over the last 5 quarters it ranged from $1.6M (Q3 2026) to $31.1M (Q4 2025).